Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.

dc.contributor.authorIm, Young-Hyuck
dc.contributor.authorUslu, Ruchan
dc.contributor.authorLee, Keun Seok
dc.contributor.authorNagarkar, Rajnish Vasant
dc.contributor.authorSohn, Joohyuk
dc.contributor.authorSevinc, Alper
dc.contributor.authorAltundag, Kadri
dc.contributor.authorChang, Yuan-Ching
dc.contributor.authorAbdel-Razeq, Hikmat
dc.contributor.authorIm, Seock-Ah
dc.contributor.authorJeong, Joon
dc.contributor.authorPark, Ho Yong
dc.contributor.authorArpornwirat, Wichit
dc.contributor.authorBastick, Patricia A.
dc.contributor.authorTuan Anh Le
dc.contributor.authorArikan, Ozlem Ocak
dc.contributor.authorXue, Hong-Ling
dc.contributor.authorCanatar, Aycin
dc.contributor.authorValenti, Roberta
dc.contributor.authorKim, Sung-Bae
dc.date.accessioned2019-10-27T22:26:56Z
dc.date.available2019-10-27T22:26:56Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, ILen_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.doi10.1200/jco.2015.33.15_suppl.e11579
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://doi.org/10.1200/jco.2015.33.15_suppl.e11579
dc.identifier.urihttps://hdl.handle.net/11454/50504
dc.identifier.volume33en_US
dc.identifier.wosWOS:000358036902197en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleClinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.en_US
dc.typeConference Objecten_US

Dosyalar